+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cystic Fibrosis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Cystic Fibrosis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Cystic Fibrosis Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6084162
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cystic Fibrosis Market grew from USD 6.44 billion in 2024 to USD 7.07 billion in 2025. It is expected to continue growing at a CAGR of 9.56%, reaching USD 11.14 billion by 2030.

Cystic fibrosis (CF) persists as a complex, life-limiting genetic disorder that demands a multidisciplinary approach to care. Unlike conditions with singular treatment pathways, CF management necessitates a combination of pharmacological therapies, nutritional support, and personalized interventions that address the root cause of the disease. Recent advances in molecular diagnostics and targeted treatments have ushered in a new era of precision medicine, yet the heterogeneity of patient responses underscores the need for continued innovation. This executive summary presents a synthesized view of the current CF landscape, highlighting pivotal shifts in therapeutic modalities, regulatory influences, and market dynamics. By exploring the interplay of evolving drug classes, administration routes, patient demographics, and technological breakthroughs, stakeholders can identify actionable insights to enhance patient outcomes and optimize resource allocation. Throughout this analysis, emphasis remains on delivering clear, actionable intelligence without speculative projections, ensuring decision-makers can navigate challenges and capitalize on emerging opportunities. Transitioning seamlessly into an exploration of transformative shifts, this overview lays the foundation for a nuanced understanding of how the CF ecosystem is adapting to both scientific progress and external pressures.

Transformative Shifts Redimagining Cystic Fibrosis Care

In recent years, the cystic fibrosis market has undergone transformative shifts driven by breakthroughs in genetic therapies and novel small molecule modulators. As a result of enhanced genomic screening programs, clinicians can now identify specific CFTR gene mutations with unprecedented accuracy, enabling tailored interventions that directly target underlying protein dysfunction. Moreover, collaborative research efforts between academic institutions and biopharmaceutical companies have accelerated the translation of gene editing platforms into early-stage clinical applications. Concurrently, the integration of digital health solutions-such as remote monitoring of pulmonary function and adherence tracking via connected devices-has redefined patient engagement, empowering individuals to participate actively in their treatment plans. Furthermore, regulatory agencies have adopted adaptive pathways, expediting access to therapies for high-need patients while maintaining rigorous safety standards. These structural changes have created a more dynamic ecosystem in which innovation is both encouraged and efficiently channeled toward unmet medical needs. As the market continues to embrace precision medicine and real-world evidence frameworks, the industry stands poised to deliver improved clinical outcomes. Transitioning to the next section, it is essential to assess how external policy measures, such as proposed tariffs, might influence this evolving landscape.

Assessing the Cumulative Impact of U.S. Tariffs in 2025

As of 2025, the introduction of new United States tariffs on imported active pharmaceutical ingredients and specialized medical devices has generated multifaceted implications for the cystic fibrosis community. Firstly, increased manufacturing costs have prompted domestic suppliers to reevaluate sourcing strategies, leading to strategic partnerships between local contract manufacturers and established pharmaceutical companies. Secondly, price adjustments have necessitated renegotiations of procurement contracts within hospital systems and specialty clinics, with payers demanding more robust pharmacoeconomic data to justify reimbursement. Thirdly, emerging players in gene editing and chemical therapeutics have experienced heightened pressure to internalize certain production steps, accelerating vertical integration initiatives aimed at insulating operations from external tariff fluctuations. In addition, patient advocacy groups are intensifying dialogues with policy makers to mitigate adverse affordability effects, reinforcing the importance of rebate programs and co-pay assistance. Collectively, these adjustments underscore the complex interplay between policy decisions and patient access. Looking ahead, stakeholders must calibrate supply chain resilience and financial models to ensure that therapeutic innovation remains accessible, before turning to granular insights from market segmentation.

Key Insights Across Market Segmentation

A nuanced understanding of the cystic fibrosis market emerges through segmentation by drug type, route of administration, patient age group, therapeutic focus, disease severity, end user, technology, and distribution channel. In terms of drug classes, anti-infectives-including antibiotics, antifungals, and antivirals-address chronic and acute infections, while bronchodilators such as long-acting and short-acting formulations facilitate airway clearance. CFTR modulators target the defective protein at its molecular core and represent a paradigm shift in disease-modifying therapy. Complementary approaches include mucolytics to reduce sputum viscosity and pancreatic enzyme supplements that enhance nutrient absorption. When evaluating administration routes, inhaled therapies delivered via inhalers and nebulizers offer localized pulmonary effects, whereas oral and parenteral systems serve systemic needs. From a demographic perspective, the distinction between adult and pediatric populations influences dosing regimens and therapeutic priorities. Therapeutic areas range from genetic and nutritional therapies that address root causes and metabolic demands, respectively, to symptomatic treatments that manage disease manifestations. Disease severity segmentation highlights varying clinical pathways for mild, moderate, and severe presentations. End users span homecare environments, private and public hospitals, and specialty clinics, each with unique operational requirements. On the technology front, chemical therapeutics coexist with emerging gene editing platforms. Finally, distribution channels encompass hospital pharmacies, online pharmacies and retail outlets, each shaping accessibility and patient adherence.

Critical Regional Dynamics Shaping Growth

Regional dynamics exert a profound influence on cystic fibrosis care, reflecting variations in healthcare infrastructure, reimbursement frameworks, and epidemiological patterns. In the Americas, well-established screening programs and high patient awareness have fostered rapid adoption of CFTR modulators and advanced diagnostics, although payers increasingly scrutinize cost-effectiveness. Europe, Middle East & Africa present a heterogeneous landscape wherein Western European markets lead in reimbursement of gene therapy trials, while emerging economies prioritize expansion of basic care services and nutritional support. Across the Asia-Pacific region, increased public-private collaborations are driving infrastructure upgrades for specialized clinics, yet access remains uneven due to regulatory complexity and varying economic maturity. Moreover, cultural factors and differing definitions of standard care impact patient engagement strategies. Consequently, stakeholders must tailor product portfolios and market entry approaches to reflect region-specific reimbursement pathways, distribution networks, and healthcare delivery models.

Leading Companies Driving Industry Progress

Competitive intensity in cystic fibrosis is anchored by a diverse mix of multinational pharmaceutical giants, biotechnology innovators, and diagnostic specialists. AbbVie Inc. leverages its broad immunology portfolio to explore anti-inflammatory adjutants, while Alcresta Therapeutics, Inc. focuses on novel anti-infective peptides tailored for resistant pathogens. AlgiPharma AS pioneers inhaled biotherapeutics that aim to modulate mucosal immunity. AstraZeneca PLC integrates CFTR modulator research with its respiratory franchise, and CHIESI Farmaceutici S.p.A. emphasizes combination therapies to simplify treatment regimens. Elucigene Diagnostics by Delta Diagnostics (UK) Limited specializes in rapid genetic testing kits that accelerate mutation identification. F. Hoffmann-La Roche AG exploits its platform for small molecule optimization, collaborating extensively on companion diagnostics. Galapagos NV and Gilead Sciences, Inc. both pursue next-generation CFTR modulators with improved mutation coverage. Johnson & Johnson Services, Inc. brings device expertise to delivery systems, while NovaBiotics Ltd. investigates antimicrobial peptides for chronic infection control. Novartis AG explores gene therapy modalities, complemented by Pharmaxis Ltd.’s focus on lysophospholipid inhibitors. PTC Therapeutics, Inc. advances read-through compounds for nonsense mutations. Vertex Pharmaceuticals Incorporated remains at the forefront with its established CFTR modulator franchise, continuously refining efficacy and safety profiles. Together, these entities drive a robust innovation pipeline.

Actionable Recommendations for Industry Leaders

Industry leaders seeking to strengthen their position in the cystic fibrosis space should pursue a multifaceted strategy. First, forging alliances between gene editing pioneers and chemical therapeutic developers can accelerate combination regimens that address both root cause and symptomatic relief. Second, investing in digital health platforms-such as remote spirometry and AI-enabled adherence analytics-can differentiate product offerings and enhance long-term patient engagement. Third, expanding patient support services through telehealth and homecare integration will improve continuity of care, particularly in regions with limited specialty clinic access. Fourth, engaging early with payers to generate robust pharmacoeconomic evidence will streamline reimbursement negotiations and bolster formulary placements. Fifth, anticipating regulatory shifts by participating in adaptive pathway pilots can expedite market entry while reinforcing safety monitoring. Sixth, diversifying manufacturing footprints to mitigate tariff impacts and supply chain disruptions will sustain product availability. Finally, aligning with patient advocacy networks to co-develop education initiatives will strengthen brand loyalty and amplify real-world evidence capture.

Conclusion

The cystic fibrosis landscape is characterized by rapid scientific progress, evolving policy frameworks, and diverse patient needs. As novel therapies transition from experimental to standard of care, collaboration across stakeholders-biopharmaceutical companies, clinicians, payers, and patient foundations-remains essential. Embracing precision medicine approaches will drive meaningful clinical improvements, yet scalability demands thoughtful resource allocation and supply chain resilience. Attention to regional nuances in infrastructure and reimbursement will determine the pace of adoption, while strategic partnerships can accelerate technology transfer and broaden access. Ultimately, a patient-centered ethos that integrates advanced therapeutics, digital support tools, and comprehensive care pathways will define success. By synthesizing insights from market segmentation, regional trends, and competitive positioning, decision-makers can navigate complexities and capitalize on opportunities that enhance both business performance and patient outcomes.

Market Segmentation & Coverage

This research report categorizes the Cystic Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Anti-Infectives
    • Antibiotics
    • Antifungals
    • Antivirals
  • Bronchodilators
    • Long-Acting Bronchodilators
    • Short-Acting Bronchodilators
  • CFTR Modulators
  • Mucolytics
  • Pancreatic Enzyme Supplements
  • Inhaled
    • Inhalers
    • Nebulizers
  • Oral
  • Parenteral
  • Adults
  • Pediatrics
  • Genetic Therapy
  • Nutritional Therapy
  • Symptomatic Therapy
  • Mild
  • Moderate
  • Severe
  • Homecare
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Specialty Clinics
  • Chemical Therapeutics
  • Gene Editing
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

This research report categorizes the Cystic Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Cystic Fibrosis Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Alcresta Therapeutics, Inc.
  • AlgiPharma AS
  • AstraZeneca PLC
  • CHIESI Farmaceutici S.p.A.
  • Elucigene Diagnostics by Delta Diagnostics (UK) Limited
  • F. Hoffmann-La Roche AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • NovaBiotics Ltd.
  • Novartis AG
  • Pharmaxis Ltd.
  • PTC Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cystic Fibrosis Market, by Drug Type
8.1. Introduction
8.2. Anti-Infectives
8.2.1. Antibiotics
8.2.2. Antifungals
8.2.3. Antivirals
8.3. Bronchodilators
8.3.1. Long-Acting Bronchodilators
8.3.2. Short-Acting Bronchodilators
8.4. CFTR Modulators
8.5. Mucolytics
8.6. Pancreatic Enzyme Supplements
9. Cystic Fibrosis Market, by Route Of Administration
9.1. Introduction
9.2. Inhaled
9.2.1. Inhalers
9.2.2. Nebulizers
9.3. Oral
9.4. Parenteral
10. Cystic Fibrosis Market, by Patient Age Group
10.1. Introduction
10.2. Adults
10.3. Pediatrics
11. Cystic Fibrosis Market, by Therapeutic Area
11.1. Introduction
11.2. Genetic Therapy
11.3. Nutritional Therapy
11.4. Symptomatic Therapy
12. Cystic Fibrosis Market, by Disease Severity
12.1. Introduction
12.2. Mild
12.3. Moderate
12.4. Severe
13. Cystic Fibrosis Market, by End User
13.1. Introduction
13.2. Homecare
13.3. Hospitals
13.3.1. Private Hospitals
13.3.2. Public Hospitals
13.4. Specialty Clinics
14. Cystic Fibrosis Market, by Technology Used
14.1. Introduction
14.2. Chemical Therapeutics
14.3. Gene Editing
15. Cystic Fibrosis Market, by Distribution Channel
15.1. Introduction
15.2. Hospital Pharmacies
15.3. Online Pharmacies
15.4. Retail Pharmacies
16. Americas Cystic Fibrosis Market
16.1. Introduction
16.2. Argentina
16.3. Brazil
16.4. Canada
16.5. Mexico
16.6. United States
17. Asia-Pacific Cystic Fibrosis Market
17.1. Introduction
17.2. Australia
17.3. China
17.4. India
17.5. Indonesia
17.6. Japan
17.7. Malaysia
17.8. Philippines
17.9. Singapore
17.10. South Korea
17.11. Taiwan
17.12. Thailand
17.13. Vietnam
18. Europe, Middle East & Africa Cystic Fibrosis Market
18.1. Introduction
18.2. Denmark
18.3. Egypt
18.4. Finland
18.5. France
18.6. Germany
18.7. Israel
18.8. Italy
18.9. Netherlands
18.10. Nigeria
18.11. Norway
18.12. Poland
18.13. Qatar
18.14. Russia
18.15. Saudi Arabia
18.16. South Africa
18.17. Spain
18.18. Sweden
18.19. Switzerland
18.20. Turkey
18.21. United Arab Emirates
18.22. United Kingdom
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AbbVie Inc.
19.3.2. Alcresta Therapeutics, Inc.
19.3.3. AlgiPharma AS
19.3.4. AstraZeneca PLC
19.3.5. CHIESI Farmaceutici S.p.A.
19.3.6. Elucigene Diagnostics by Delta Diagnostics (UK) Limited
19.3.7. F. Hoffmann-La Roche AG
19.3.8. Galapagos NV
19.3.9. Gilead Sciences, Inc.
19.3.10. Johnson & Johnson Services, Inc.
19.3.11. NovaBiotics Ltd.
19.3.12. Novartis AG
19.3.13. Pharmaxis Ltd.
19.3.14. PTC Therapeutics, Inc.
19.3.15. Vertex Pharmaceuticals Incorporated
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. CYSTIC FIBROSIS MARKET MULTI-CURRENCY
FIGURE 2. CYSTIC FIBROSIS MARKET MULTI-LANGUAGE
FIGURE 3. CYSTIC FIBROSIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 22. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CYSTIC FIBROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CFTR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PANCREATIC ENZYME SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALED, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GENETIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY NUTRITIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SYMPTOMATIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY CHEMICAL THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 90. CANADA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 91. CANADA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. CANADA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 93. CANADA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. CANADA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 95. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 96. CANADA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. CANADA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. CANADA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 99. CANADA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 102. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 105. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 106. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 107. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 108. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 111. MEXICO CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 151. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 152. CHINA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 153. CHINA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. CHINA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 155. CHINA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. CHINA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 157. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 158. CHINA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. CHINA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 160. CHINA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 161. CHINA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. INDIA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 164. INDIA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 165. INDIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. INDIA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 167. INDIA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. INDIA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 169. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 170. INDIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. INDIA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 172. INDIA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 173. INDIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 188. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 189. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 191. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 193. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 194. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 196. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 197. JAPAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 247. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 259. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 260. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 261. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 263. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 264. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 265. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 266. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 268. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 269. THAILAND CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 295. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 296. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 297. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 298. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 300. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 301. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 302. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 303. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 305. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 306. DENMARK CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 308. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 309. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 310. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 312. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 313. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 314. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 315. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 317. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 318. EGYPT CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 319. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 320. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 321. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 322. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 323. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 324. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 325. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 326. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 327. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 328. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 329. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 330. FINLAND CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 332. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 333. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 334. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 335. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 336. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 337. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 338. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 339. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 340. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 341. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 342. FRANCE CYSTIC FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 343. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 344. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2030 (USD MILLION)
TABLE 345. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 346. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 347. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY INHALED, 2018-2030 (USD MILLION)
TABLE 348. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 349. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 350. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2030 (USD MILLION)
TABLE 351. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 352. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 353. GERMANY CYSTIC FIBROSIS MARKET SIZE, BY TECHNOLOGY USED, 2018-2030 (USD MILLION)
TABLE 354. GERMANY CYSTIC FIBROSIS MARKET S

Companies Mentioned

  • AbbVie Inc.
  • Alcresta Therapeutics, Inc.
  • AlgiPharma AS
  • AstraZeneca PLC
  • CHIESI Farmaceutici S.p.A.
  • Elucigene Diagnostics by Delta Diagnostics (UK) Limited
  • F. Hoffmann-La Roche AG
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • NovaBiotics Ltd.
  • Novartis AG
  • Pharmaxis Ltd.
  • PTC Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated

Methodology

Loading
LOADING...

Related Topics

Related Reports

Cystic Fibrosis Market by Drug Class, Route of Administration - Global Forecast 2025-2030 - Product Image

Cystic Fibrosis Market by Drug Class, Route of Administration - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Cystic Fibrosis Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Pancreatic Enzyme Supplements), Route of Administration (Oral), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Cystic Fibrosis Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Pancreatic Enzyme Supplements), Route of Administration (Oral), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 90 Pages
  • Global
From
Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2024-2032 - Product Image

Cystic Fibrosis Therapeutics Market Report by Drug Class, Drug Molecule Type, Route of Administration, End-User, and Region 2024-2032

  • Report
  • 147 Pages
  • Global
From
Cystic Fibrosis Devices Market by Product, End User, Age Group, Therapy - Global Forecast 2025-2030 - Product Image

Cystic Fibrosis Devices Market by Product, End User, Age Group, Therapy - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 203 Pages
  • Global
From

About the Cystic Fibrosis Drug Market

The Cystic Fibrosis Drug market is a subset of the larger Respiratory Drug market. It is composed of treatments and therapies designed to address the symptoms of cystic fibrosis, a genetic disorder that affects the lungs and digestive system. These drugs are used to reduce the amount of mucus in the lungs, improve breathing, and reduce the risk of infection. They may also be used to treat other symptoms, such as malnutrition, dehydration, and vitamin deficiencies. The Cystic Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of the major players in the market include Vertex Pharmaceuticals, Gilead Sciences, Novartis, and GlaxoSmithKline. Other companies, such as AbbVie, Merck, and Pfizer, are also active in the market. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.